Trial Profile
Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Mar 2020
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions
- Acronyms TRISTAR
- 20 Mar 2018 New trial record